The death of a 19-year-old student in London, linked to the weight-loss drug tirzepatide, has intensified concerns about the potential risks associated with GLP-1 agonist medications. Josephine Nasr, who was overweight, suffered a fatal irregular heart rhythm in her dorm room in September 2025. An inquest concluded that the prescribed tirzepatide likely caused low blood sugar, leading to an electrolyte imbalance that, combined with an underlying heart condition, triggered the cardiac arrhythmia.
This incident follows a report indicating that weight-loss jabs have been associated with at least 216 deaths in Britain, with 120 of those cases involving tirzepatide. Approximately 2.5 million Britons use these medications, medically known as GLP-1 agonists, which are prescribed for weight loss and have also shown benefits in protecting against various diseases.
The Medicines and Healthcare products Regulatory Agency (MHRA) has updated its guidance to highlight the risk of severe acute pancreatitis, a rare but potentially deadly inflammation of the pancreas, associated with GLP-1 drugs. While common side effects include nausea, vomiting, diarrhea, and constipation, more severe complications like dehydration and allergic reactions can also occur. The MHRA received 1,296 reports of pancreatitis, including various forms, between 2007 and October 2025, with 19 resulting in death, representing about 1.5% of those reports.
Despite these concerns, the MHRA stressed that the risk remains small, noting that 25.4 million packs of GLP-1 drugs have been dispensed. Patient information leaflets for drugs like Wegovy, Ozempic, and Mounjaro already warn of acute pancreatitis affecting up to one in 100 patients. The agency has updated guidance to emphasize reports of necrotizing pancreatitis and fatal outcomes, urging healthcare professionals to be alert to this risk. Patients experiencing severe symptoms such as intense stomach pain radiating to the back, nausea, and vomiting are advised to seek urgent medical care and report their symptoms.
Other potential risks associated with GLP-1s include acute gallstone disease, which can lead to infections, and allergic reactions, including anaphylaxis. Anaphylaxis accounts for approximately 20 deaths per year in the UK and can manifest with rapid onset symptoms like breathing difficulties and facial swelling. While officials emphasize that severe side effects are rare for the majority of patients, they advise vigilance.
Experts noted that the reported deaths should be interpreted with caution. Professor Naveed Sattar of the University of Glasgow highlighted that individuals prescribed these medications often have pre-existing conditions like obesity, diabetes, and heart disease, which themselves increase the risk of serious illness and premature death. He added that when millions of individuals at higher risk take a medicine, some will inevitably experience adverse events, regardless of the drug's role. Dr. Marie Spreckley from the University of Cambridge reiterated that while the medicines offer substantial health benefits when prescribed appropriately, rare but serious adverse effects can occur, underscoring the need for continued monitoring.